Last reviewed · How we verify
NCT03499197
Heart TIMING - Heart Transplantation IMagING
trial testing cardiac magnetic resonance imaging in Heart Transplant Failure and Rejection in 100 participants. Status unknown.
15 January 2021
Quick facts
| Lead sponsor | Semmelweis University Heart and Vascular Center |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 15 January 2018 |
| Primary completion | 15 January 2021 |
| Estimated completion | 15 January 2026 |
| Sites | 1 location across Hungary |
Drugs / interventions tested
- cardiac magnetic resonance imaging
Conditions studied
- Heart Transplant Failure and Rejection — all drugs for Heart Transplant Failure and Rejection →
- Magnetic Resonance Imaging — all drugs for Magnetic Resonance Imaging →
Sponsor
Semmelweis University Heart and Vascular Center
Who can join
18 and older, any sex, with Heart Transplant Failure and Rejection or Magnetic Resonance Imaging. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The cardiac allograft rejection (CAR) and cardiac allograft vasculopathy (CAV) significantly affect the prognosis of patients after heart transplantation. The aim of the present study is to investigate and differentiate the adaptive and pathological cardiovascular changes after heart transplantation using different modalities. The investigator's main purpose is to define the role of the cardiovascular imaging methods and biomarkers in the early diagnosis of CAR and CAV.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03499197
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of cardiac magnetic resonance imaging
Trials testing the same drug.
- NCT05624242 — Assessment of Right Ventricular Function by Cardiac MRI in Patients With Pulmonary Arterial Hypertension (IRMA) · completed
- NCT04663230 — Right Atrial Fibrosis in Pulmonary Hypertension · completed
Other recruiting trials for Heart Transplant Failure and Rejection
Currently open trials in the same condition.
- NCT07079735 — Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant · Phase 2, PHASE3 · recruiting
- NCT04380311 — Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant · NA · active not recruiting
- NCT03102125 — Allograft Dysfunction in Heart Transplant · Phase 4 · recruiting
- NCT03575910 — HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection · active not recruiting
Other Semmelweis University Heart and Vascular Center trials
Trials by the same sponsor.
- NCT07434193 — Biventricular or Left Bundle Branch Pacing to Assess the Effect of Cardiac Resynchronization Therapy in Patients Undergo · NA · recruiting
- NCT07296965 — Oral Microbiome in Carotid Atherosclerosis · recruiting
- NCT06501313 — PhotobiomoduLation for pAtientS With Advanced hEart failuRe · NA · not yet recruiting
- NCT05838937 — The Usefulness of Myocardial Work IndeX in ExtraCorporeal Membrane Oxygenation Patients · not yet recruiting
- NCT06173089 — REmote MOnitoring of paTiEnts witH pacEmaker or implAntable cardioverteR defibrillaTor · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03499197 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Semmelweis University Heart and Vascular Center
- Last refreshed: 17 April 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03499197.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing